Twist Bioscience Corp vs Exxon Mobil Corporation — how do they compare? Twist Bioscience Corp trades at $166.14 (market cap $10.08B), while Exxon Mobil Corporation trades at $169.44 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 68.7× Twist Bioscience Corp's market cap, and Exxon Mobil Corporation pays a 2.45% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Exxon Mobil Corporation for 99 Days on average.
| TWST | XOM | |
|---|---|---|
Market Cap | $10.08B | $692.86B |
Volume | 4,229,037 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $205.00 | $171.52 |
52-Week Low | $25.45 | $110.64 |
Typical Hold Time | 27 Days | 99 Days |
Enterprise Value | $10.01B | $724.64B |
Dividend Yield | — | 2.45% |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Exxon Mobil (XOM) trades at $164.06, down 0.26% on the day, with a bullish technical signal and strong support at $163. The company reported mixed Q2 2026 earnings, missing EPS estimates, but maintains solid profitability with a 9.07% net margin. Recent news highlights potential expansion into Venezuela's oil fields and ongoing growth in Guyana and Permian Basin assets. Cash flow from operations remains robust at $52.0 billion in 2025, though net cash flow was negative due to high capital expenditures.
XOM offers a stable dividend and growth potential from strategic investments, but faces risks from volatile oil prices and geopolitical exposure. Analyst consensus is a 'Hold' with a $169.45 price target, indicating modest upside. Revenue declines from 2022-2025 pose a concern, but projected 2026 growth to $361.1 billion may reverse the trend. The stock's valuation ratios, including a P/E of 21.69, are reasonable for the energy sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →